Systematic analysis of UBE2D3 and its association with prognosis, tumor microenvironment, and drug sensitivity in renal clear cell carcinoma

<i>UBE2D3</i> may function as a tumor suppressor in KIRC, as suggested by its downregulation in advanced stages and correlation with improved survival. Correspondingly, its loss appears to correlate with advanced disease, an immunosuppressive tumor microenvironment (TME), and unfavorable prognosis. This potential role in modulating immune cell dynamics and drug sensitivity positions <i>UBE2D3</i> as a promising biomarker for prognostication and personalized therapy selection in KIRC.